American Liver Foundation aiming to improve care for patients
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic dysfunction-associated steatotic liver disease (MASLD)…
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo at reducing markers of disease…
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be detectable using computer-based analyses of…
An initiative in the European Union (EU) aims to speed up the diagnosis of rare genetic disorders such as Alagille syndrome in newborns using…
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a living adult donor that was…
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…
Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…